Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prognosis of patients with ascites after PleurX insertion: an observational study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The cost of endoscopic treatment for walled-off pancreatic necrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To evaluate the safety of PleurX in cirrhotic patients with refractory ascites.

METHODS: We prospectively registered patients who received a PleurX catheter cirrhosis-associated refractory ascites at our department from July 2015 to November 2016. Our control group consisted of matched cirrhotic patients with refractory ascites treated with large volume paracentesis (LVP) and patients with malignant ascites treated with PleurX during the same period.

RESULTS: We included 25 patients with cirrhosis-related ascites (7 in PleurX group) and 17 with malignant ascites (14 in PleurX group). Of these, six patients had hepatocellular carcinoma and cirrhosis (5 in PleurX group). None were eligible for insertion of a TIPS or liver transplantation. The maximum duration of follow-up was (480 days) in the PleurX group and 366 days in the LVP group (median 84 and 173 days, respectively). There was no difference in mortality when comparing PleurX with LVP treatment (hazard ratios: 3.0 and 1.0, p = .23 and .96, respectively). Mortality was higher in patients with malignant ascites (p= .01). We found no significant differences in adverse events (incl. spontaneous bacterial peritonitis) or in P-albumin, P-creatinine and P-sodium between the groups.

CONCLUSION: PleurX insertion for the treatment of refractory ascites in cirrhotic patients appears to be safe. Prospective randomized trials are necessary in order to confirm these findings.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume53
Issue number3
Pages (from-to)340-344
ISSN0036-5521
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article

ID: 52668506